Ga-68 dotatateDiagnostic radiopharmaceutical
Gallium-68 DOTATATE combines a somatostatin-receptor-binding peptide with a radioactive imaging label. It is used in PET imaging to help locate tissues expressing those receptors, particularly certain neuroendocrine tumours.
What is Ga-68 dotatate?
Gallium-68 DOTATATE is a radioactive diagnostic tracer used with PET imaging to locate somatostatin-receptor-positive tissue, particularly in the assessment of selected neuroendocrine tumours. 1 2
How it works
DOTATATE binds somatostatin receptors. The attached gallium-68 produces the signal detected by the PET scanner, allowing receptor-bearing tissue to be mapped. 2
Effects studied
What does the evidence show?
The archive contains imaging research and product information. The result needs interpretation alongside the tumour type, other scans and the wider clinical picture.
A targeting molecule and an imaging signal
DOTATATE binds to somatostatin receptors, which can be present at high levels on some neuroendocrine tumour cells. Gallium-68 supplies the radioactive signal detected by PET. The combination allows clinicians to investigate receptor-bearing tissue rather than relying on anatomy alone.
What a scan can add
A receptor scan can help locate disease and contribute to staging or treatment selection in an appropriate clinical setting. It cannot identify every cancer, and not every neuroendocrine tumour has the same receptor pattern. A bright area on the scan can have other explanations and does not establish a diagnosis on its own. 1
Why imaging and treatment should not be confused
Lutetium-177 DOTATATE uses a related targeting approach but a different radioactive payload for therapy. Sharing DOTATATE in the name does not make the products interchangeable. Imaging may inform a treatment pathway, while the therapeutic decision involves additional eligibility and safety considerations.
Preparation and safety in nuclear medicine
This tracer is prepared and administered within nuclear medicine services. Radiation exposure, possible hypersensitivity and considerations around pregnancy or breastfeeding belong in the product-specific assessment. Image timing and interpretation likewise require specialist protocols; an online peptide listing cannot reproduce that clinical context. 2
Safety & status
The examination involves radiation exposure. Hypersensitivity and pregnancy or breastfeeding considerations belong in the imaging assessment. Receptor expression also varies between tumours. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Does the scan treat the tumour?
No. Gallium-68 DOTATATE is a diagnostic tracer. Lutetium-177 DOTATATE uses a related targeting approach with a therapeutic radioactive payload.
Will every cancer appear on this scan?
No. The method depends on somatostatin receptor expression, so it is not a universal cancer scan. 2
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Ga-68 dotatate: paper 10.2967/jnumed.115.163865 Research reference · Retained archive reference; not independently checked for this draft.
- Ga-68 dotatate: www.novartis.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.